Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis

Scandinavian Journal of Gastroenterology

Volumn 27, Issue 11, 1992, Pages 968-972

  Eliakim, R ^a   Karmeli, F ^a   Chorev, M ^a   Okon, E ^a   Rachmilewitz, D ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

4 aminosalicylic acid; 5 aminosalicylic acid; Acetyl 5 aminosalicylic acid; Azathioprine; Chloroquine; Cyclosporin; Ketotifen; Methotrexate; Ulcerative colitis

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AMINOSALICYLIC ACID; AMINOSALICYLIC ACID DERIVATIVE; ANTI INFLAMMATORY AGENTS, NON STEROIDAL; CHLOROQUINE; ICOSANOID; IMMUNOSUPPRESSIVE AGENT; KETOTIFEN; MESALAZINE; N-ACETYL-5-AMINOSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; P AMINOSALICYLIC ACID; AZATHIOPRINE; CYCLOSPORIN; METHOTREXATE;

ADULT; AGED; ARTICLE; BIOPSY; COLON; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; INTESTINE MUCOSA; MALE; METABOLISM; PATHOLOGY; ULCERATIVE COLITIS; CLINICAL ARTICLE; CONTROLLED STUDY; ICOSANOID METABOLISM; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION;

ADULT; AGED; AGED, 80 AND OVER; AMINOSALICYLIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; CHLOROQUINE; COLITIS, ULCERATIVE; COLON; COMPARATIVE STUDY; EICOSANOIDS; FEMALE; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL MUCOSA; KETOTIFEN; MALE; MESALAMINE; MIDDLE AGE; P-AMINOSALICYLIC ACID;

EID: 0026614597     PISSN: 00365521     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529209000172     Document Type: Article

References (47)

1. Recent developments in nonspecific inflammatory bowel disease
2. The role of the immune system in inflammatory bowel disease
3. Alterations of the immune system in ulcerative colitis and Crohn's disease
4. Mediators: release and function
5. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine
6. Increased prostaglandin production in ulcerative colitis
7. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease
8. Role of platelet activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone
9. Role of interleukin 1 in inflammatory bowel discase-enhanced production during active disease
10. Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis
11. Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid
12. Treatment of Crohn's disease with 6-mercaptopurine. A long term, randomized, double-blind study
13. Favorablc cffect of 6-mercaptopurinc on fistulas of Crohn's disease
14. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease
15. Methotrexate induces clinical and histologic remission in paticnts with refractory inflammatory bowel disease
16. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis
17. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial
18. Advances in drug therapy for inflammatory bowcl disease
19. Controlled trial of disodium cromoglycate in chronic persistent ulcerative colitis
20. Comparative trial of sulfasalazine and oral sodium cromoglycate in thc maintenance of remission in ulcerative colitis
21. Comparative trial of sodium cromoglycate enemas with prednisolone enemas in the treatment of ulcerative colitis
22. Efficacy of chloroquine in the treatment of inflammatory bowel disease [abstract]
23. Ketotifen effectively prevents mucosal damage in experimental colitis
24. Gastric mucosal damage is mediated by substance P and prevented by ketotifen, a mast cell stabilizer
25. Radioimmunological assay of prostaglandin synthetase activity
26. Effect of duodenal ulcer healing induced by omeprazole and ranitidine on the generation of gastroduodenal eicosanoids, platelet-activating factor, pepsinogen A, and gastrin in duodenal ulcer patients
27. Metabolism of arachidonic acid in acetic acid colitis in rats: similarity to human inflammatory bowel disease
28. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease
29. The biologically active leukotrienes. Biosynthesis function and pharmacology
30. Reactive oxygen metabolites as mediators in cell injury in the intestine
31. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis
32. Cyclosporine in inflammatory bowel disease
33. Use of methotrexate for refractory inflammatory bowel disease
34. 2 treated rats
35. Capacity-limited gut wall metabolism of 5-aminosalicylic acid; a therapeutically active metabolite of sulphasalazine in rats
36. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease
37. Acetylation of S-aminosalicylic acid by isolated human colonic epithelial cells
38. Double-blind comparison of 5-aminosalicylic acid and acetyl 5-aminosalicylic acid suppositories in patients with idiopathic proctitis
39. Is N-acetylation of S-aminosalicylic acid reversible in man
40. Kinetics of 5-aminosalicylic acid after jejunal installation in man
41. Sulphasalazine and the new salicylates
42. Metabolism and urinary excretion of 5-aminosalicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract
43. Clinical pharmacokinetics of sulphasalazine its metabolites and other prodrugs of 5-aminosalicylic acid
44. The release profile of a controlled release preparation of 5-aminosalicylic acid (Rawasa I) in humans
45. The effect of topical N-acetyl-5-aminosalicylic acid in ulcerative colitis
46. Possible mode of action of 5-aminosalicylic acid
47. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid